Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic

ConclusionsWith close monitoring and follow-up, ARNi therapy was a safe alternative to ACEi/ARB therapy for chronic symptomatic HFrEF when initiated within a pharmacist clinic.

http://link.springer.com/10.1007/s40256-018-0264-5

Source: American Journal of Cardiovascular Drugs - February 17, 2018 Category: Cardiology Source Type: research